Ó Gníomhaireacht Forbartha Tionscail Éireann; An Roinn Fiontar, Trádála agus Fostaíochta
Foilsithe
An t-eolas is déanaí
Teanga: Níl leagan Gaeilge den mhír seo ar fáil.
Amgen announced an investment of $100 million today for the construction of a new vial filing line with ‘state of the art’ technology and new site infrastructure at its manufacturing plant in Dun Laoghaire, Co Dublin. This investment is one of Amgen’s largest construction projects outside North America and will lead to the creation of 150 construction jobs.
The Dun Laoghaire plant specialises in formulation, aseptic drug product filling, lyophilisation, packaging as well as analytical testing using on-site laboratories. The Amgen plant in Dun Laoghaire is celebrating its 10th anniversary this year and currently employs 670 staff.
Construction on the new vial line has already begun and is due to be completed and fully operational by 2024.
Tánaiste and Minister for Enterprise, Trade and Employment Leo Varadkar TD said:
"This is fantastic news and a real testament to the 670 staff Amgen currently employs in Dun Laoghaire. This $100m investment will bring the company’s total investment in the Dublin plant to $900m . Amgen is one of the world’s leading biotechnology companies, and this investment underscores Ireland’s position as a leading global location for the sector. The announcement coincides with the company’s 10 year anniversary in Dun Laoghaire and I wish all the team the very best in their next chapter."
Speaking about today’s announcement, Paul Greene, Vice President for Regional Manufacturing said:
"At Amgen, we pride ourselves on delivering for ‘Every Patient, Every Time’ and the investment we are announcing today will enable us to serve more patients here in Ireland and all over the world. Since we acquired the manufacturing plant in Dun Laoghaire, we have now invested $900m to expand and update our production facilities and to bring in new products and capabilities. This investment is a testament to our commitment to our local community and our highly skilled workforce."
Martin Shanahan said, CEO of IDA Ireland said:
"I’d like to congratulate Amgen on its 10 year anniversary in Dun Laoghaire which is being marked by a significant investment in its manufacturing facility. This investment illustrates Amgen’s ongoing and welcome commitment to Ireland and is a further endorsement by a global leader in Ireland’s Biopharmaceutical ecosystem."
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World’s Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron’s.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
IDA Ireland Press Office press@pressofficeidaireland.com